Department of Clinical Pharmacy; Department of Family Medicine, University of Tennessee Health Science Center, Memphis.
Department of Family Medicine, University of Tennessee Health Science Center, Memphis.
Am J Med. 2018 Nov;131(11):1304-1306. doi: 10.1016/j.amjmed.2018.05.043. Epub 2018 Jul 2.
The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.
美国食品和药物管理局最近批准了几种新的胰高血糖素样肽-1（GLP-1）激动剂，单独使用或与各种胰岛素产品联合使用。这是一系列文章中的第二篇，本文将描述 GLP-1 激动剂类产品的潜在优缺点。
